Date: 2016-04-18
Type of information: Opening of new premises
Compound:
Company: British Biosimilars Association (BBA) (UK)
Therapeutic area:
Type agreement: opening of new premises
Action mechanism:
Disease:
Details: * On April 18, 2016, a new industry body, the British Biosimilars Association (BBA), has been formally launched with the sole focus of increasing the understanding and use of biosimilar medicines in the UK.
The BBA is the expert sector group of the British Generic Manufacturers Association (BGMA) exclusively focused on biosimilar medicines. BBA members’ core focus will be ensuring patients can benefit from these lifesaving and life changing medicines to the same extent as those elsewhere in Europe. Currently, the UK lags behind some European countries in the take-up of biosimilar medicines. There are seven biosimilar molecules on the market in the UK (somatropin, follitropin alfa, filgrastim, infliximab, epotein alfa, insulin glargine and etanercept). However, this is set to increase due to a number of factors including patent expiries, increasing clinical awareness and knowledge
as well as supportive guidance from organisations such as the National Institute for Health and Care Excellence (NICE) to generate confidence in using these products.
Financial terms:
Latest news:
